Epidemiology and Prevention of Neonatal Candidiasis: Fluconazole for All Neonates?

  • David A. Kaufman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 659)


The epidemiology and prevention of invasive Candida infections (ICI) depends largely on risk factors and the role they play in infection control and identifying high-risk patients for prevention. Prevention of ICI is critical, as there is significant mortality and even with successful eradication, neurodevelopmental impairment occurs in 57% of survivors weighing less than1000 g (Stoll et al., 2004 Benjamin et al., 2006). It is important to know local invasive fungal infection data in your unit, as the incidence in available literature lacks important key information regarding practices that may increase or decrease the incidence.


Preterm Infant Central Venous Catheter Antifungal Prophylaxis Bone Marrow Transplant Patient Neurodevelopmental Impairment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aghai, Z.H., Mudduluru, M., Nakhla, T.A., Amendolia, B., Longo, D., Kemble, N., Kaki, S., Sutsko, R., Saslow, J.G., & Stahl, G.E. (2006). Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol, (26), 550–555.PubMedCrossRefGoogle Scholar
  2. Benjamin, D.K., DeLong, E., Cotten, C.M., Garges, H.P., Steinbach, W.J., & Clark, R.H. (2004). Mortality following blood culture in premature infants: increased with gram-negative bacteremia and candidemia, but not gram-positive bacteremia. J Perinatol, (24), 175–180.PubMedCrossRefGoogle Scholar
  3. Benjamin, D.K., Jr., DeLong, E.R., Steinbach, W.J., Cotton, C.M., Walsh, T.J., & Clark, R.H. (2003). Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics, (112), 543–547.PubMedCrossRefGoogle Scholar
  4. Benjamin, D.K., Jr., Stoll, B.J., Fanaroff, A.A., McDonald, S.A., Oh, W., Higgins, R.D., Duara, S., Poole, K., Laptook, A., & Goldberg, R. (2006). Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics, 117(1), 84–92.PubMedCrossRefGoogle Scholar
  5. Bertini, G., Perugi, S., Dani, C., Filippi, L., Pratesi, S., & Rubaltelli, F.F. (2005). Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr, (147), 162–165.PubMedCrossRefGoogle Scholar
  6. Burwell, L.A., Kaufman, D., Blakely, J., Stoll, B.J., & Fridkin, S.K. (2006). Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics, (118), e1019–e1026.PubMedCrossRefGoogle Scholar
  7. Clancy, C.J., Staley, B., & Nguyen, M.H. (2006). In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother, (50), 3496–3498.PubMedCrossRefGoogle Scholar
  8. Clerihew, L., Austin, N., & McGuire, W. (2007). Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev, CD003850.Google Scholar
  9. Clerihew, L., Lamagni, T.L., Brocklehurst, P., & McGuire, W. (2006). Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed, (91), F188–F192.PubMedCrossRefGoogle Scholar
  10. Clerihew, L. & McGuire, W. (2007). Antifungal prophylaxis for very-low-birth-weight infants: UK national survey. Arch Dis Child Fetal Neonatal Ed, 93(3), F238–F239.PubMedCrossRefGoogle Scholar
  11. Cotten, C.M., McDonald, S., Stoll, B., Goldberg, R.N., Poole, K., & BenjaminJr., D.K. (2006). The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics, (118), 717–722.PubMedCrossRefGoogle Scholar
  12. El Masry, F.A., Neal, T.J., & Subhedar, N.V. (2002). Risk factors for invasive fungal infection in neonates. Acta Paediatr, (91), 198–202.PubMedCrossRefGoogle Scholar
  13. Ellepola, A.N. & Samaranayake, L.P. (1998). Adhesion of oral C. albicans to human buccal epithelial cells following limited exposure to antifungal agents. J Oral Pathol Med, (27), 325–332.PubMedCrossRefGoogle Scholar
  14. Faergemann, J. & Laufen, H. (1993). Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol, (18), 102–106.PubMedCrossRefGoogle Scholar
  15. Fairchild, K.D., Tomkoria, S., Sharp, E.C., & Mena, F.V. (2002). Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J, (21), 39–43.PubMedCrossRefGoogle Scholar
  16. Feja, K.N., Wu, F., Roberts, K., Loughrey, M., Nesin, M., Larson, E., la-Latta, P., Haas, J., Cimiotti, J., & Saiman, L. (2005). Risk factors for candidemia in critically Ill infants: a matched case-control study. J Pediatr, (147), 156–161.PubMedCrossRefGoogle Scholar
  17. Fridkin, S.K., Kaufman, D., Edwards, J.R., Shetty, S., & Horan, T. (2006). Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004. Pediatrics, (117), 1680–1687.PubMedCrossRefGoogle Scholar
  18. Ghannoum, M.A., Filler, S.G., Ibrahim, A.S., Fu, Y., & Edwards, J.E., Jr. (1992). Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B. Antimicrob Agents Chemother, (36), 2239–2244.PubMedGoogle Scholar
  19. Guillet, R., Stoll, B.J., Cotten, C.M., Gantz, M., McDonald, S., Poole, W.K., & Phelps, D.L. (2006). Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics, (117), e137–e142.PubMedCrossRefGoogle Scholar
  20. Hack, M. (2006). Neonatology fellowship training in research pertaining to development and follow-up. J Perinatol, 26(Suppl 2), S30–S33.PubMedCrossRefGoogle Scholar
  21. Hazen, K.C., Coleman, E., & Wu, G. (2000). Influence of fluconazole at subinhibitory concentrations on cell surface hydrophobicity and phagocytosis of Candida albicans. FEMS Microbiol Lett, (183), 89–94.PubMedCrossRefGoogle Scholar
  22. Healy, C.M., Baker, C.J., Zaccaria, E., & Campbell, J.R. (2005). Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr, (147), 166–171.PubMedCrossRefGoogle Scholar
  23. Healy, C.M., Campbell, J.R., Zaccaria, E., & Baker, C.J. (2008). Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics, (121), 703–710.PubMedCrossRefGoogle Scholar
  24. Hof, H. (2008). Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Updat, 11(1–2), 25–31.PubMedCrossRefGoogle Scholar
  25. Houang, E.T., Chappatte, O., Byrne, D., Macrae, P.V., & Thorpe, J.E. (1990). Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother, (34), 909–910.PubMedGoogle Scholar
  26. Hylander, M.A., Strobino, D.M., & Dhanireddy, R. (1998). Human milk feedings and infection among very low birth weight infants. Pediatrics, (102), E38.PubMedCrossRefGoogle Scholar
  27. Johnson, D.E., Thompson, T.R., Green, T.P., & Ferrieri, P. (1984). Systemic candidiasis in very low-birth-weight infants (less than 1,500 grams). Pediatrics, (73), 138–143.PubMedGoogle Scholar
  28. Johnsson, H. & Ewald, U. (2004). The rate of candidaemia in preterm infants born at a gestational age of 23–28 weeks is inversely correlated to gestational age. Acta Paediatr, (93), 954–958.PubMedCrossRefGoogle Scholar
  29. Kaufman, D.A. (2008a). Prevention of invasive Candida infections in preterm infants: the time is now. Expert Rev Anti Infect Ther, (6), 393–399.PubMedCrossRefGoogle Scholar
  30. Kaufman, D. (2008b). Fluconazole prophylaxis decreases the combined outcome of invasive Candida infections or mortality in preterm infants. Pediatrics, (122), 1158–1159.PubMedCrossRefGoogle Scholar
  31. Kaufman, D.A. (2008c). Fluconazole prophylaxis: can we eliminate invasive Candida infections in the neonatal ICU? Curr Opin Pediatr, 20(3), 332–340.PubMedCrossRefGoogle Scholar
  32. Kaufman, D., Boyle, R., Hazen, K.C., Patrie, J.T., Robinson, M., & Donowitz, L.G. (2001). Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med, (345), 1660–1666.PubMedCrossRefGoogle Scholar
  33. Kaufman, D., Boyle, R., Hazen, K.C., Patrie, J.T., Robinson, M., & Grossman, L.B. (2005). Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr, (147), 172–179.PubMedCrossRefGoogle Scholar
  34. Kaufman, D., Boyle, R., Robinson, M., & Grossman, L.B. (2003). Long-term safety of intravenous prophylactic fluconazole use in preterm infants less than 1000 grams. Pediatr Res, (53), 484A. Ref Type: Abstract.Google Scholar
  35. Kaufman, D.A., Gurka, M.J., Hazen, K.C., Boyle, R., Robinson, M., & Grossman, L.B. (2006). Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth. Pediatr Infect Dis J, (25), 733–737.PubMedCrossRefGoogle Scholar
  36. Kaufman, D.A., Manzoni, P., Gurka, M.J., & Grossman, L.B. (2007). Antifungal Prophylaxis in the Neonatal Intensive Care Unit (NICU). Curr Pediatr Rev, 277–288.Google Scholar
  37. Kicklighter, S.D., Springer, S.C., Cox, T., Hulsey, T.C., & Turner, R.B. (2001). Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics, (107), 293–298.PubMedCrossRefGoogle Scholar
  38. Kojic, E.M. & Darouiche, R.O. (2004). Candida infections of medical devices. Clin Microbiol Rev, (17), 255–267.PubMedCrossRefGoogle Scholar
  39. Koks, C.H., Crommentuyn, K.M., Hoetelmans, R.M., Mathot, R.A., & Beijnen, J.H. (2001). Can fluconazole concentrations in saliva be used for therapeutic drug monitoring? Ther Drug Monit, (23), 449–453.PubMedCrossRefGoogle Scholar
  40. Kramer, M.S., Platt, R.W., Wen, S.W., Joseph, K.S., Allen, A., Abrahamowicz, M., Blondel, B., & Breart, G. (2001). A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics, (108), E35.PubMedCrossRefGoogle Scholar
  41. Leibovitz, E., Iuster-Reicher, A., Amitai, M., & Mogilner, B. (1992). Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin Infect Dis, (14), 485–491.PubMedGoogle Scholar
  42. Makhoul, I.R., Bental, Y., Weisbrod, M., Sujov, P., Lusky, A., & Reichman, B. (2007). Candidal versus bacterial late-onset sepsis in very low birthweight infants in Israel: a national survey. J Hosp Infect, (65), 237–243.PubMedCrossRefGoogle Scholar
  43. Makhoul, I.R., Sujov, P., Smolkin, T., Lusky, A., & Reichman, B. (2002). Epidemiological, clinical, and microbiological characteristics of late- onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics, (109), 34–39.PubMedCrossRefGoogle Scholar
  44. Makhoul, I.R., Sujov, P., Smolkin, T., Lusky, A., & Reichman, B. (2005). Pathogen-specific early mortality in very low birth weight infants with late-onset sepsis: a national survey. Clin Infect Dis, (40), 218–224.PubMedCrossRefGoogle Scholar
  45. Manzoni, P., Arisio, R., Mostert, M., Leonessa, M., Farina, D., Latino, M.A., & Gomirato, G. (2006a). Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics, (117), e22–e32.PubMedCrossRefGoogle Scholar
  46. Manzoni, P., Farina, D., Antonielli, D.E., Leonessa, M.L., Gomirato, G., & Arisio, R. (2006b). An association between anatomic site of Candida colonization and risk of invasive candidiasis exists also in preterm neonates in neonatal intensive care unit. Diagn Microbiol Infect Dis, (56), 459–460.PubMedCrossRefGoogle Scholar
  47. Manzoni, P., Farina, D., Galletto, P., Leonessa, M., Priolo, C., Arisio, R., & Gomirato, G. (2007a). Type and number of sites colonized by fungi and risk of progression to invasive fungal infection in preterm neonates in neonatal intensive care unit. J Perinat Med, (35), 220–226.PubMedCrossRefGoogle Scholar
  48. Manzoni, P., Farina, D., Leonessa, M., d’Oulx, E.A., Galletto, P., Mostert, M., Miniero, R., & Gomirato, G. (2006c). Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics, (118), 2359–2364.PubMedCrossRefGoogle Scholar
  49. Manzoni, P., Leonessa, M., Galletto, P., Latino, M.A., Arisio, R., Maule, M., Agriesti, G., Gastaldo, L., Gallo, E., Mostert, E., & Farina, D. (2008). Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J, (27), 731–737.PubMedCrossRefGoogle Scholar
  50. Manzoni, P., Mostert, M., Leonessa, M.L., Priolo, C., Farina, D., Monetti, C., Latino, M.A., & Gomirato., G. (2006d). Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis, (42), 1735–1742.PubMedCrossRefGoogle Scholar
  51. Manzoni, P., Stolfi, I., Pugni, L., Decembrino, L., Magnani, C., Vetrano, G., Tridapalli, E., Corona, G., Giovannozzi, C., Farina, D., Arisio, R., Merletti, F., Maule, M., Mosca, F., Pedicino, R., Stronati, M., Mostert, M., & Gomirato, G. (2007b). A multi-center, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med, (356), 2483–2495.PubMedCrossRefGoogle Scholar
  52. Marr, K.A., Seidel, K., Slavin, M.A., Bowden, R.A., Schoch, H.G., Flowers, M.E., Corey, L., & Boeckh, M. (2000b). Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood, (96), 2055–2061.PubMedGoogle Scholar
  53. Marr, K.A., Seidel, K., White, T.C., & Bowden, R.A. (2000a). Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis, (181), 309–316.PubMedCrossRefGoogle Scholar
  54. Ozturk, M.A., Gunes, T., Koklu, E., Cetin, N., & Koc, N. (2006). Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses, (49), 484–492.PubMedCrossRefGoogle Scholar
  55. O’Grady, M.J. & Dempsey, E.M. (2008). Antifungal prophylaxis for the prevention of neonatal candidiasis? Acta Paediatr, (97), 430–433.PubMedCrossRefGoogle Scholar
  56. Pappas, P.G., Rex, J.H., Sobel, J.D., Filler, S.G., Dismukes, W.E., Walsh, T.J., & Edwards, J.E. (2004). Guidelines for treatment of candidiasis. Clin Infect Dis, (38), 161–189.PubMedCrossRefGoogle Scholar
  57. Parikh, T.B., Nanavati, R.N., Patankar, C.V., Suman Rao, P.N., Bisure, K., Udani, R.H., & Mehta, P. (2007). Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr, (44), 830–837.PubMedGoogle Scholar
  58. Candidiasis. In Pickering, L., Baker, C.J., Long, S.S., & McMillian, J.A., (Eds.) (2006). Red Book. Report of the Committee on Infectious Diseases. (27th ed.). Elk Grove Villiage, IL: American Academy of Pediatrics. pp. 246.Google Scholar
  59. Procianoy, R.S., Eneas, M.V., & Silveira, R.C. (2006). Empiric guidelines for treatment of Candida infection in high-risk neonates. Eur J Pediatr, (165), 422–423.PubMedCrossRefGoogle Scholar
  60. Saiman, L., Ludington, E., Dawson, J.D., Patterson, J.E., Rangel-Frausto, S., Wiblin, R.T., Blumberg, H.M., Pfaller, M., Rinaldi, M., Edwards, J.E., Wenzel, R.P., & Jarvis, W. (2001). Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J, (20), 1119–1124.PubMedCrossRefGoogle Scholar
  61. Saiman, L., Ludington, E., Pfaller, M., Rangel-Frausto, S., Wiblin, R.T., Dawson, J., Blumberg, H.M., Patterson, J.E., Rinaldi, M., Edwards, J.E., Wenzel, R.P., & Jarvis, W. (2000). Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J, (19), 319–324.PubMedCrossRefGoogle Scholar
  62. Sarvikivi, E., Lyytikainen, O., Soll, D.R., Pujol, C., Pfaller, M.A., Richardson, M., Koukila-Kahkola, P., Luukkainen, P., & Saxen, H. (2005). Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol, (43), 2729–2735.PubMedCrossRefGoogle Scholar
  63. Schuman, P., Capps, L., Peng, G., Vazquez, J., el Sadr, W., Goldman, A.I., Alston, B., Besch, C.L., Vaughn, A., Thompson, M.A., Cobb, M.N., Kerkering, T., & Sobel, J.D. (1997). Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med, (126), 689–696.PubMedGoogle Scholar
  64. Sims, M.E., Yoo, Y., You, H., Salminen, C., & Walther, F.J. (1988). Prophylactic oral nystatin and fungal infections in very-low- birthweight infants. Am J Perinatol, (5), 33–36.PubMedCrossRefGoogle Scholar
  65. Smith, P.B., Morgan, J., Benjamin, J.D., Fridkin, S.K., Sanza, L.T., Harrison, L.H., Sofair, A.N., Huie-White, S., & Benjamin, D.K., Jr. (2007). Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J, (26), 197–200.PubMedCrossRefGoogle Scholar
  66. Sobel, J.D., Wiesenfeld, H.C., Martens, M., Danna, P., Hooton, T.M., Rompalo, A., Sperling, M., Livengood, C., III, Horowitz, B., Von Thron, J., Edwards, L., Panzer, H., & Chu, T.C. (2004). Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med, (351), 876–883.PubMedCrossRefGoogle Scholar
  67. Stoll, B.J., Hansen, N.I., Adams-Chapman, I., Fanaroff, A.A., Hintz, S.R., Vohr, B., & Higgins, R.D. (2004). Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA, (292), 2357–2365.PubMedCrossRefGoogle Scholar
  68. Stoll, B.J., Hansen, N., Fanaroff, A.A., Wright, L.L., Carlo, W.A., Ehrenkranz, R.A., Lemons, J.A., Donovan, E.F., Stark, A.R., Tyson, J.E., Oh, W., Bauer, C.R., Korones, S.B., Shankaran, S., Laptook, A.R., Stevenson, D.K., Papile, L.A., & Poole, W.K. (2002). Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics, (110), 285–291.PubMedCrossRefGoogle Scholar
  69. Stoll, B.J., Temprosa, M., Tyson, J.E., Papile, L.A., Wright, L.L., Bauer, C.R., Donovan, E.F., Korones, S.B., Lemons, J.A., Fanaroff, A.A., Stevenson, D.K., Oh, W., Ehrenkranz, R.A., Shankaran, S., & Verter, J. (1999). Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics, (104), e63.PubMedCrossRefGoogle Scholar
  70. Uko, S., Soghier, L.M., Vega, M., Marsh, J., Reinersman, G.T., Herring, L., Dave, V.A., Nafday, S., & Brion, L.P. (2006). Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics, (117), 1243–1252.PubMedCrossRefGoogle Scholar
  71. Vaden, S.L., Heit, M.C., Hawkins, E.C., Manaugh, C., & Riviere, J.E. (1997). Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. J Vet Pharmacol Ther, (20), 181–186.PubMedCrossRefGoogle Scholar
  72. Walsh, T.J., Gonzalez, C.E., Piscitelli, S., Bacher, J.D., Peter, J., Torres, R., Shetti, D., Katsov, V., Kligys, K., & Lyman, C.A. (2000). Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol, (38), 2369–2373.PubMedGoogle Scholar
  73. Weitkamp, J.H., Ozdas, A., Lafleur, B., & Potts, A.L. (2008). Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol, (286), 405–411.CrossRefGoogle Scholar
  74. Weitkamp, J.H., Poets, C.F., Sievers, R., Musswessels, E., Groneck, P., Thomas, P., & Bartmann, P. (1998). Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection, (26), 11–15.PubMedCrossRefGoogle Scholar
  75. White, T.C., Marr, K.A., & Bowden, R.A. (1998). Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev, (11), 382–402.PubMedGoogle Scholar
  76. Yoder, B.A., Sutton, D.A., Winter, V., & Coalson, J.J. (2004). Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model. Pediatr Infect Dis J, (23), 687–688.PubMedCrossRefGoogle Scholar
  77. Zaoutis, T.E., Heydon, K., Localio, R., Walsh, T.J., & Feudtner, C. (2007). Outcomes attributable to neonatal candidiasis. Clin Infect Dis, (44), 1187–1193.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Neonatology, Department of PediatricsUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations